Appello Pharmaceuticals, Inc.

In June 2018, Deerfield invested in Appello Pharmaceuticals Inc., an early stage spin-out from Vanderbilt University that is advancing a new small molecule therapy for the symptomatic treatment of Parkinson’s disease. The investment supports the development of the positive allosteric modulators (“PAMs”) of the metabotropic glutamate receptor subtype 4 (“mGlu4”).

Deerfield Supports Patient Care Advancing Ophthalmology Company Graybug Vision

New York, NY – May 2, 2016 – Deerfield announced today it led the $44.5 million Series B financing of Graybug Vision, Inc. Graybug Vision is an early stage pharmaceutical company committed to developing therapies that may transform care for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma.  Graybug Vision’s technology was first developed at Johns Hopkins University and has been spun out into a startup venture. 

Graybug Vision is developing ophthalmology products enabling potentially twice per year dosing using its novel injectable depot technology.  The company recently completed a 6 month study in animals for its lead program, GB-102, a therapy for twice-yearly treatment of wet AMD.  This preclinical study demonstrated the ability of Graybug Vision’s proprietary technology to deliver a small molecule drug that blocks both VEGF and PDGF for over 6 months after a single intravitreal injection in rabbits.  The technology achieves the 6 month release profile without inflammation or toxicity after an intravitreal injection – an unprecedented result for a non-steroid drug delivered to the eye.

“We are excited to work with Graybug Vision to help it advance its therapies to market. We believe the technology developed by the Johns Hopkins founders and the Graybug Vision team has the ability to change the standard of care for patients suffering from sight threatening eye disease,” stated Cameron Wheeler, PhD and Principal at Deerfield. 

“We are pleased to have Deerfield as a supporter of our technology and company, and we believe the firm has significant skills which will add to our Board and development of Graybug Vision,” stated Jeffrey L. Cleland, PhD, President and CEO of Graybug Vision, Inc. 

About Graybug Vision

Graybug Vision is developing novel products for the treatment of ocular diseases.  Graybug Vision’s technology enables the delivery of compounds to the eye up to twice per year and was co-developed by Graybug Vision founder Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with Graybug Vision cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD.  Graybug Vision’s lead product, GB-102, is being developed for twice a year treatment of wet AMD patients.  Graybug Vision’s second product consists of compounds with intraocular pressure lowering and neuroprotection that may be administered to the subconjunctiva twice per year for the treatment of glaucoma.  For more information, please visit www.graybug.com.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com

Contacts

Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]

Graybug Vision

Graybug Vision is an early stage pharmaceutical company committed to developing therapies that may transform care for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma. Graybug Vision’s technology was first developed at Johns Hopkins University and has been spun out into a startup venture. Graybug Vision is developing ophthalmology products enabling potentially twice per year dosing using its novel injectable depot technology.

KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) for the treatment of pain, ADHD and other CNS diseases through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs.

Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system. Its lead program is in Parkinson’s Disease and is entering Phase II trials. The goal of the trial is to use gene therapy to reduce the amount of levodopa that patients are required to take to maintain mobility which will reduce several negative side effects.

Deerfield Provides Debt Facility to Depomed

NEW YORK, NY – March 12, 2015 – Deerfield announced a $375 million debt investment in Depomed, Inc. as part of $575 million facility to support Depomed’s $1.05 billion acquisition of the U.S. rights to NUCYNTA® from Janssen Pharmaceuticals.  Depomed has announced that the Nucynta transaction will more than double its revenue base and that it is immediately accretive to earnings.

Deerfield will provide a $375 million facility which will accrue interest quarterly and amortize in annual increments from the third through the seventh anniversaries of the closing.  The company has the right to prepay the facility in tranches at its discretion.

“The acquisition of NUCYNTA is transformational for Depomed.  Our facility has been structured to avoid equity dilution and provide flexible terms for repayment and future acquisitions.”  said Alex Karnal, Partner at Deerfield Management.

“We are excited to partner with Deerfield, one of the premier investors that provides growth capital for pharmaceutical firms like Depomed.  The facility with Deerfield and Pharmakon allows Depomed to close the Nucynta transaction without dilution to our shareholders while we continue to look for assets to further grow our business,” stated Jim Schoeneck, President and CEO of Depomed.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor®(diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed’s proven, proprietary Acuform®drug delivery technology.  Depomed has announced the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals,Inc. which is expected to close in the second quarter of 2015. The NUCYNTA franchise includes NUCYNTA®ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy(DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA®(tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Additional information about Depomed may be found at www.Depomed.com.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com

Contacts

Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]

Assertio

DepoMed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. In a transformative transaction, the company agreed to acquire the U.S. rights to NUCYNTA, a drug for severe pain, from Janssen Pharmaceuticals for $1.05 billion.

To finance the purchase, Deerfield and Pharmakon structured a flexible 7 year debt facility. The total facility was $575 million of which Deerfield provided $375 million.

Alimera Sciences

Alimera Sciences, Inc. is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Its lead product, Iluvien, treats diabetic macular edema in patients who have previously been treated with corticosteroids.

Aerie Pharmaceuticals

Aerie Pharmaceuticals is a clinical stage pharmaceutical company developing first in class glaucoma therapies including Rhopressa™ and Roclatan™. The company required funding in order to complete the registration trials needed for FDA approval and to prepare for commercial launch activities.

Deerfield Management Announces a $125 million Facility with Aerie Pharmaceuticals

NEW YORK,  September 9, 2014 — Deerfield Management Company announced today it has committed to invest $125 million in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) through senior secured convertible notes. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. The facility provides Aerie with capital for the continued advancement of development activities for the Company’s clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.

Under the terms of the financing, the notes will be secured and accrue interest at a rate of 1.75% per annum until maturity in September of 2021. The notes are convertible at a conversion price representing a 30% premium over the closing price of Aerie stock on September 8, 2014, resulting in a conversion price of $24.80 per share.

“We believe this level of financing at favorable terms will be significantly beneficial to Aerie. We now have adequate financial resources to complete all of our known clinical requirements for RhopressaTM and RoclatanTM, and to commercialize RhopressaTM later in 2017 if our trials are successful. This financing also provides us with flexibility for potential strategic product in-licenses or acquisitions as we continue to build Aerie into what we believe may become a major ophthalmic pharmaceutical company. We are deeply appreciative of Deerfield’s confidence in Aerie’s product candidates and growth prospects,” commented Vicente Anido, Jr.,Ph.D., Chairman and Chief Executive Officer at Aerie.

“We are excited by the opportunity to work with Aerie’s strong management team and to contribute to the advancement of a leading scientific platform in ophthalmology,” commented William Slattery, Partner,Deerfield Management.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com

Contacts

Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]